Yahoo
NasdaqCM - Nasdaq Real Time Price USD

aTyr Pharma, Inc. (ATYR)

0.4976 +0.0003 (+0.06%)
As of 11:02:30 AM EDT. Market Open.
Chart Range Bar
Loading chart for ATYR
  • Previous Close 0.4973
  • Open 0.5100
  • Bid 0.3502 x 200
  • Ask 0.6500 x 200
  • Day's Range 0.4872 - 0.5100
  • 52 Week Range 0.3950 - 6.5000
  • Volume 201,611
  • Avg. Volume 1,317,685
  • Market Cap (intraday) 48.808M
  • Beta (5Y Monthly) 0.53
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6300
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.86

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

atyrpharma.com

58

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ATYR
36.45%
S&P 500 (^GSPC)
12.35%

1-Year Return

ATYR
90.89%
S&P 500 (^GSPC)
18.41%

3-Year Return

ATYR
70.02%
S&P 500 (^GSPC)
72.54%

5-Year Return

ATYR
90.61%
S&P 500 (^GSPC)
70.37%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -10.31M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-25M
-20M
-15M
-10M
-5M
0
-10000.0%
-5000.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

1.00
2.86 Average
0.4976 Current
7.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/20/2026
Analyst Freedom Broker
Rating Action Upgrade
Rating Buy
Price Action Raises
Price Target 1 -> 3.5

Statistics

View More

Valuation Measures

Annual
As of 9/3/2026
  • Market Cap

    49.44M

  • Enterprise Value

    3.32M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    259.58

  • Price/Book (mrq)

    1.01

  • Enterprise Value/Revenue

    17.46

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -46.58%

  • Return on Equity (ttm)

    -98.68%

  • Revenue (ttm)

    190k

  • Net Income Avi to Common (ttm)

    -60.81M

  • Diluted EPS (ttm)

    -0.6300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    57.42M

  • Total Debt/Equity (mrq)

    23.25%

  • Levered Free Cash Flow (ttm)

    -31.71M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.4976 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: